Carbapenems are an important class of drugs very much useful in the therapy of multidrug-resistant gram-negative pathogens. Though these are available for the past 30 years, they can be administered only parenterally, which can reduce the compliance. Tebipenem-pivoxil (TBPM-PI; Orapenem), a prodrug, is the first oral carbapenem. It has been a promising drug in the therapy of drug-resistant respiratory infections and complicated urinary tract infections. It will also be useful in reducing the incidence of central line associated blood stream infections (CLABSI) and improving the rate of treatment completion.
Yao Q, Wang J, Ciu T, et al. Antibacterial properties of tebipenem pivoxil tablet, a new oral carbapenem preparation against a variety of pathogenic bacteria in vitro and in vivo. Molecules 2016;21(1):62. DOI: 10.3390/molecules21010062.
Pucci MJ, Jain A, Utley L, et al. Tebipenem, the first oral carbapenem antibiotic. Expert Rev Anti Infec Ther 2018;16(7):513–522. DOI: 10.1080/14787210.2018.1496821.
Tang C, Cai L, Liu S, et al. Crystalo structure of tebipenem pivoxil. Acta Cryst 2018;74(Pt 9):1215–1217.
Kato K, Shirasaka Y, Kuraoka E, et al. Intestinal absorption mechanism of tebipenem pivoxil, a novel oral carbapenem: involvement of human OATP family in apical membrane transport. Molecular Pharmaceutics 2010;7(5):1747–1756. DOI: 10.1021/mp100130b.
Rubio A, Pucci MJ, Jain A. Characterisaion of SPR994, an orally available carbapenem, with activity comparable to intravenously administered carbapenems. ACS Infect Dis 2018;4(10):1436–1438. DOI: 10.1021/acsinfecdis.8b00188.
Sugita R. Good transfer of tebipenem into middle ear effusion conduces to the favorable clinical outcomes of tebipenem pivoxil in pediatric patients with acute otitis media. J Infect Chemother 2013;19(3):465–471. DOI: 10.1007/s10156-012-0513-5.
El-Gamal MI, Oh CH. Current status of carbapenem antibiotics. Curr Topics Med Chem 2010;10(18):1882–1897. DOI: 10.2174/156802610793176639.
Sato N, Kijima K, Koresawa T, et al. Population pharmacokinetics of tebipenem pivoxil (ME1211), a novel oral carbapenem antibiotic, in pediatric patients with otolaryngological infection or pneumonia. Drug Metab Pharmacokinet 2008;23(6):434–446. DOI: 10.2133/dmpk.23.434.
Kijima K, Morita J, Suzuki K, et al. Pharmacokinetics of tebipenem pivoxil, a novel oral carbapenem antibiotic, in experimental animals. Jpn J Antibiot 2009;62(3):214–240.
Nakashima M, Morito J, Aizawa K. Pharmacokinetics and safety of oral carbapenem antibiotic tebipenem pivoxel tablets in healthy male volunteers. Jpn J Chemother 2009;57(S-1):82–89.
Sunakawa K. Pharmacological properties and clinical performance of the novel oral carbapenem antimicrobial drug, “Tebipenem pivoxil” (Orapenem® fine granules 10% for pediatric use). Jpn J Chemother 2009;57(4):279–294.
Sakata H, Kuroki H, Ouchi K, et al. Pediatric community—acquired pneumonia treated with a three-day course of tebipenem pivoxil. J Infect Chemother 2017;23(5):307. DOI: 10.1016/j.jiac.2017.01. 009-311.
Kataoka H, Kasahara H, Sasagawa Y, et al. Evaluation of safety and efficacy of tebipenem pivoxil granules for pediatric in pneumonia, otitis media and sinusitis. Jpn J Antibiot 2016;69(1):53–76.
Iwata S, Ouchi K, Iwai N, et al. An open clinical study of tebipenem pivoxil in children with bacterial pneumonia. Jpn J Chemother 2009;57(1):137–150.
Shihyakugari A, Miki A, Nakamoto N, et al. First case report of suspected onset of convulsive seizures due to co-administration of valproic acid and tebipenem. Int J Clin Pharmacol Ther 2015;53(1): 92–96. DOI: 10.5414/CP202188.